{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:25:34Z","timestamp":1747221934297,"version":"3.40.5"},"reference-count":31,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Bras Pneumol."],"abstract":"<jats:p>Objective: Lymphangioleiomyomatosis (LAM) is a rare, destructive disease of the lungs with a limited number of determinants of disease activity, which are a critical need for clinical trials. FGF23 has been implicated in several chronic pulmonary diseases. We aimed to determine the association between serum FGF23 levels and pulmonary function in a cohort of patients with LAM. Methods: This was a descriptive single-center study in which subjects with LAM and controls with unreported lung disease were recruited. Serum FGF23 levels were measured in all subjects. Clinical data, including pulmonary function testing, were retrospectively obtained from electronic medical records of LAM subjects. Associations between FGF23 levels and clinical features of LAM were explored via nonparametric hypothesis testing. Results: The sample comprised 37 subjects with LAM and 16 controls. FGF23 levels were higher in the LAM group than in the control group. In the LAM group, FGF23 levels above the optimal cutoff point distinguished 33% of the subjects who had nondiagnostic VEGF-D levels. Lower FGF23 levels were associated with impaired DLCO (p = 0.04), particularly for those with isolated diffusion impairment with no other spirometric abnormalities (p = 0.04). Conclusions: Our results suggest that FGF23 is associated with pulmonary diffusion abnormalities in LAM patients and elicit novel mechanisms of LAM pathogenesis. FGF23 alone or in combination with other molecules needs to be validated as a biomarker of LAM activity in future clinical research.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20220356","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T19:08:41Z","timestamp":1680548921000},"page":"e20220356","source":"Crossref","is-referenced-by-count":0,"title":["Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion"],"prefix":"10.36416","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8636-0845","authenticated-orcid":false,"given":"Anthony","family":"J Esposito1,2","sequence":"first","affiliation":[{"name":"1. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston (MA) USA. 2. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Northwestern University, Feinberg School of Medicine, Chicago (IL) USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4302-0443","authenticated-orcid":false,"given":"Jewel","family":"Imani1","sequence":"additional","affiliation":[{"name":"1. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston (MA) USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9493-8814","authenticated-orcid":false,"given":"Shikshya","family":"Shrestha1","sequence":"additional","affiliation":[{"name":"1. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston (MA) USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2183-2040","authenticated-orcid":false,"given":"Shefali","family":"Bagwe1","sequence":"additional","affiliation":[{"name":"1. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston (MA) USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7947-1511","authenticated-orcid":false,"given":"Anthony","family":"M Lamattina1","sequence":"additional","affiliation":[{"name":"1. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston (MA) USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7176-679X","authenticated-orcid":false,"given":"Marina","family":"Vivero3","sequence":"additional","affiliation":[{"name":"3. Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston (MA) USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2319-0009","authenticated-orcid":false,"given":"Hilary","family":"J Goldberg1","sequence":"additional","affiliation":[{"name":"1. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston (MA) USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4622-618X","authenticated-orcid":false,"given":"Ivan","family":"O Rosas4","sequence":"additional","affiliation":[{"name":"4. Department of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine, Baylor College of Medicine, Houston (TX) USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-6699","authenticated-orcid":false,"given":"Elizabeth","family":"P Henske1","sequence":"additional","affiliation":[{"name":"1. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston (MA) USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2929-5589","authenticated-orcid":false,"given":"Souheil","family":"Y El-Chemaly1","sequence":"additional","affiliation":[{"name":"1. Department of Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston (MA) USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22288","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1.            Johnson SR. Lymphangioleiomyomatosis. Eur Respir J. 2006;27(5):1056-1065. https:\/\/doi.org\/10.1183\/09031936.06.00113303","DOI":"10.1183\/09031936.06.00113303"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2.            Moss J, Avila NA, Barnes PM, Litzenberger RA, Bechtle J, Brooks PG, et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med. 2001;164(4):669-671. https:\/\/doi.org\/10.1164\/ajrccm.164.4.2101154","DOI":"10.1164\/ajrccm.164.4.2101154"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3.            Cudzilo CJ, Szczesniak RD, Brody AS, Rattan MS, Krueger DA, Bissler JJ, et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest. 2013;144(2):578-585. https:\/\/doi.org\/10.1378\/chest.12-2813","DOI":"10.1378\/chest.12-2813"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4.            Henske EP, J\u00f3\u017awiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016;2:16035. https:\/\/doi.org\/10.1038\/nrdp.2016.35","DOI":"10.1038\/nrdp.2016.35"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5.            Cui Y, Steagall WK, Lamattina AM, Pacheco-Rodriguez G, Stylianou M, Kidambi P, et al. Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation. Cancer Res. 2017;77(6):1492-1502. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2755","DOI":"10.1158\/0008-5472.can-16-2755"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6.            Seyama K, Kumasaka T, Souma S, Sato T, Kurihara M, Mitani K, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol. 2006;4(3):143-152. https:\/\/doi.org\/10.1089\/lrb.2006.4.143","DOI":"10.1089\/lrb.2006.4.143"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7.            Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):199-200. https:\/\/doi.org\/10.1056\/NEJMc0707517","DOI":"10.1056\/nejmc0707517"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8.            Young LR, Vandyke R, Gulleman PM, Inoue Y, Brown KK, Schmidt LS, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010;138(3):674-681. https:\/\/doi.org\/10.1378\/chest.10-0573","DOI":"10.1378\/chest.10-0573"},{"key":"ref8","unstructured":"9.            Courtwright AM, Baldi BG, Kidambi P, Cui Y, Lamattina AM, Villalba JA, et al. Characterization of lymphangioleiomyomatosis patients with discordance between spirometric and diffusion measurements of pulmonary function. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(3):206-212."},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10.          Lamattina AM, Poli S, Kidambi P, Bagwe S, Courtwright A, Louis PH, et al. Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis. Orphanet J Rare Dis. 2019;14(1):72. https:\/\/doi.org\/10.1186\/s13023-019-1050-4","DOI":"10.1186\/s13023-019-1050-4"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11.          Matthew BP, Hasani AM, Chen YC, Pirooznia M, Stylianou M, Rollison SF, et al. Ultra-Small Lung Cysts Impair Diffusion Without Obstructing Air Flow in Lymphangioleiomyomatosis. Chest. 2021;160(1):199-208. https:\/\/doi.org\/10.1016\/j.chest.2021.01.077","DOI":"10.1016\/j.chest.2021.01.077"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12.          Taveira-Dasilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Bone mineral density in lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2005;171(1):61-67. https:\/\/doi.org\/10.1164\/rccm.200406-701OC","DOI":"10.1164\/rccm.200406-701oc"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13.          Guo YC, Yuan Q. Fibroblast growth factor 23 and bone mineralisation. Int J Oral Sci. 2015;7(1):8-13. https:\/\/doi.org\/10.1038\/ijos.2015.1","DOI":"10.1038\/ijos.2015.1"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14.          Krick S, Grabner A, Baumlin N, Yanucil C, Helton S, Grosche A, et al. Fibroblast growth factor 23 and Klotho contribute to airway inflammation. Eur Respir J. 2018;52(1):1800236. https:\/\/doi.org\/10.1183\/13993003.00236-2018","DOI":"10.1183\/13993003.00236-2018"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15.          Barnes JW, Duncan D, Helton S, Hutcheson S, Kurundkar D, Logsdon NJ, et al. Role of fibroblast growth factor 23 and klotho cross talk in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2019;317(1):L141-L154. https:\/\/doi.org\/10.1152\/ajplung.00246.2018","DOI":"10.1152\/ajplung.00246.2018"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16.          McCormack FX, Gupta N, Finlay GR, Young LR, Taveira-DaSilva AM, Glasgow CG, et al. Official American Thoracic Society\/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. Am J Respir Crit Care Med. 2016;194(6):748-761. https:\/\/doi.org\/10.1164\/rccm.201607-1384ST","DOI":"10.1164\/rccm.201607-1384st"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17.          Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200(8):e70-e88. https:\/\/doi.org\/10.1164\/rccm.201908-1590ST","DOI":"10.1164\/rccm.201908-1590st"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18.          Culver BH, Graham BL, Coates AL, Wanger J, Berry CE, Clarke PK, et al. Recommendations for a Standardized Pulmonary Function Report. An Official American Thoracic Society Technical Statement. Am J Respir Crit Care Med. 2017;196(11):1463-1472. https:\/\/doi.org\/10.1164\/rccm.201710-1981ST","DOI":"10.1164\/rccm.201710-1981st"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19.          Razzaque MS. FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player?. Am J Physiol Renal Physiol. 2009;296(3):F470-F476. https:\/\/doi.org\/10.1152\/ajprenal.90538.2008","DOI":"10.1152\/ajprenal.90538.2008"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20.          Gulati S, Wells JM, Urdaneta GP, Balestrini K, Vital I, Tovar K, et al. Fibroblast Growth Factor 23 is Associated with a Frequent Exacerbator Phenotype in COPD: A Cross-Sectional Pilot Study. Int J Mol Sci. 2019;20(9):2292. https:\/\/doi.org\/10.3390\/ijms20092292","DOI":"10.3390\/ijms20092292"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21.          Easter M, Garth J, Harris ES, Shei RJ, Helton ES, Wei Y, et al. Fibroblast Growth Factor Receptor 4 Deficiency Mediates Airway Inflammation in the Adult Healthy Lung?. Front Med (Lausanne). 2020;7:317. https:\/\/doi.org\/10.3389\/fmed.2020.00317","DOI":"10.3389\/fmed.2020.00317"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22.          Buendia-Roldan I, Machuca N, Mej\u00eda M, Maldonado M, Pardo A, Selman M. Lower levels of \u03b1-Klotho in serum are associated with decreased lung function in individuals with interstitial lung abnormalities. Sci Rep. 2019;9(1):10801. https:\/\/doi.org\/10.1038\/s41598-019-47199-0","DOI":"10.1038\/s41598-019-47199-0"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23.          Shrestha S, Adib E, Imani J, Aguiar DJ, Lamattina AM, Tassew DD, et al. Angiotensin II receptor type 1 blockade regulates Klotho expression to induce TSC2-deficient cell death. J Biol Chem. 2022;298(11):102580. https:\/\/doi.org\/10.1016\/j.jbc.2022.102580","DOI":"10.1016\/j.jbc.2022.102580"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24.          Richter B, Faul C. FGF23 Actions on Target Tissues-With and Without Klotho. Front Endocrinol (Lausanne). 2018;9:189. https:\/\/doi.org\/10.3389\/fendo.2018.00189","DOI":"10.3389\/fendo.2018.00189"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25.          Hunninghake GM, Hatabu H, Okajima Y, Gao W, Dupuis J, Latourelle JC, et al. MUC5B promoter polymorphism and interstitial lung abnormalities. N Engl J Med. 2013;368(23):2192-2200. https:\/\/doi.org\/10.1056\/NEJMoa1216076","DOI":"10.1056\/nejmoa1216076"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26.          Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309(21):2232-2239. https:\/\/doi.org\/10.1001\/jama.2013.5827","DOI":"10.1001\/jama.2013.5827"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27.          Nijmeh J, El-Chemaly S, Henske EP. Emerging biomarkers of lymphangioleiomyomatosis. Expert Rev Respir Med. 2018;12(2):95-102. https:\/\/doi.org\/10.1080\/17476348.2018.1409622","DOI":"10.1080\/17476348.2018.1409622"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28.          El-Chemaly S, Henske EP. The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials. Expert Rev Respir Med. 2015;9(2):195-204. https:\/\/doi.org\/10.1586\/17476348.2015.1024663","DOI":"10.1586\/17476348.2015.1024663"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.          Lamattina AM, Taveira-Dasilva A, Goldberg HJ, Bagwe S, Cui Y, Rosas IO, et al. Circulating Biomarkers From the Phase 1 Trial of Sirolimus and Autophagy Inhibition for Patients With Lymphangioleiomyomatosis. Chest. 2018;154(5):1070-1082. https:\/\/doi.org\/10.1016\/j.chest.2018.08.1029","DOI":"10.1016\/j.chest.2018.08.1029"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.          Hirose M, Matsumuro A, Arai T, Sugimoto C, Akira M, Kitaichi M, et al. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis. PLoS One. 2019;14(2):e0212776. https:\/\/doi.org\/10.1371\/journal.pone.0212776","DOI":"10.1371\/journal.pone.0212776"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"31.          Miller S, Coveney C, Johnson J, Farmaki AE, Gupta N, Tobin MD, et al. The vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis. Eur Respir J. 2018;52(5):1800951. https:\/\/doi.org\/10.1183\/13993003.00951-2018","DOI":"10.1183\/13993003.00951-2018"}],"container-title":["Jornal Brasileiro de Pneumologia"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T19:08:47Z","timestamp":1680548927000},"score":1,"resource":{"primary":{"URL":"https:\/\/jornaldepneumologia.com.br\/details\/3821\/en-US\/lymphangioleiomyomatosis--circulating-levels-of-fgf23-and-pulmonary-diffusion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":31,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20220356","relation":{},"ISSN":["1806-3756"],"issn-type":[{"type":"electronic","value":"1806-3756"}],"subject":[],"published":{"date-parts":[[2023,4,3]]}}}